Pharsight

Bayer Hlthcare patents expiration

1. Adempas patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7173037 BAYER HLTHCARE Carbamate-substituted pyrazolopyridines
Dec, 2026

(2 years from now)

US10662188 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
Feb, 2034

(9 years from now)

US11203593 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
Feb, 2034

(9 years from now)

Drugs and Companies using RIOCIGUAT ingredient

Market Authorisation Date: 08 October, 2013

Treatment: Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who f...

Dosage: TABLET;ORAL

How can I launch a generic of ADEMPAS before it's drug patent expiration?
More Information on Dosage

ADEMPAS family patents

Family Patents

2. Angeliq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8906890 BAYER HLTHCARE Very low-dosed solid oral dosage forms for HRT
Oct, 2031

(7 years from now)

Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient

Market Authorisation Date: 28 September, 2005

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ANGELIQ before it's drug patent expiration?
More Information on Dosage

ANGELIQ family patents

Family Patents

3. Astepro Allergy patents expiration

ASTEPRO ALLERGY Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Nov, 2025

(1 year, 8 months from now)

US9919050 BAYER HLTHCARE Compositions comprising azelastine
Nov, 2025

(1 year, 8 months from now)

US8071073 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Jun, 2028

(4 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: Otc use: allergy symptom reliever; Temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

ASTEPRO ALLERGY family patents

Family Patents

4. Beyaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6441168 BAYER HLTHCARE Stable crystalline salts of 5-methyltetrahydrofolic acid
Jul, 2022

(1 year, 6 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7163931 BAYER HLTHCARE Compositions of estrogen-cyclodextrin complexes
Mar, 2022

(1 year, 11 months ago)

US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(5 years from now)

US11617751 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Jul, 2030

(6 years from now)

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 24 September, 2010

Treatment: Prevention of pregnancy; Raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnan...

Dosage: TABLET;ORAL

How can I launch a generic of BEYAZ before it's drug patent expiration?
More Information on Dosage

BEYAZ family patents

Family Patents

5. Kerendia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 9, 2026
M (M) Sep 1, 2025

Drugs and Companies using FINERENONE ingredient

NCE-1 date: 2025-07-09

Market Authorisation Date: 09 July, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

KERENDIA family patents

Family Patents

6. Kyleena patents expiration

KYLEENA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7252839 BAYER HLTHCARE Delivery system and a manufacturing process of a delivery system
Nov, 2023

(3 months ago)

US11628088 BAYER HLTHCARE Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection
Feb, 2027

(2 years from now)

US9615965 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US10561524 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US10987244 BAYER HLTHCARE Inserter
Apr, 2031

(7 years from now)

US9668912 BAYER HLTHCARE Inserter
Apr, 2031

(7 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 16 September, 2016

Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to rele...

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

KYLEENA family patents

Family Patents

7. Levitra patents expiration

LEVITRA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8841446 BAYER HLTHCARE Medicaments containing vardenafil hydrochloride trihydrate
Jul, 2023

(7 months ago)

US8273876 BAYER HLTHCARE Medicaments containing vardenafil hydrochloride trihydrate
Jul, 2027

(3 years from now)

Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Market Authorisation Date: 19 August, 2003

Treatment: Treatement of erectiile dysfunction by administering a film-coated tablet

Dosage: TABLET;ORAL

How can I launch a generic of LEVITRA before it's drug patent expiration?
More Information on Dosage

LEVITRA family patents

Family Patents

8. Mirena patents expiration

MIRENA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561524 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US9615965 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US9668912 BAYER HLTHCARE Inserter
Apr, 2031

(7 years from now)

US10987244 BAYER HLTHCARE Inserter
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule (D) Aug 20, 2023

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 06 December, 2000

Treatment: A method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the h...

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

MIRENA family patents

Family Patents

9. Natazia patents expiration

NATAZIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071577 BAYER HLTHCARE Multi-phase contraceptive preparation based on a natural estrogen
May, 2026

(2 years from now)

US8153616 BAYER HLTHCARE Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
Jan, 2028

(3 years from now)

Drugs and Companies using DIENOGEST; ESTRADIOL VALERATE ingredient

Market Authorisation Date: 06 May, 2010

Treatment: Prevention of pregnancy; Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception

Dosage: TABLET;ORAL

How can I launch a generic of NATAZIA before it's drug patent expiration?
More Information on Dosage

NATAZIA family patents

Family Patents

10. Nexavar patents expiration

NEXAVAR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8877933 BAYER HLTHCARE Thermodynamically stable form of a tosylate salt
Dec, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618141 BAYER HLTHCARE Aryl ureas with angiogenesis inhibiting activity
Feb, 2023

(1 year, 13 days ago)

US9737488 BAYER HLTHCARE Pharmaceutical composition for the treatment of cancer
Sep, 2028

(4 years from now)

Drugs and Companies using SORAFENIB TOSYLATE ingredient

Market Authorisation Date: 20 December, 2005

Treatment: Treatment of advanced renal cell carcinoma; Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; Treatment of unresec...

Dosage: TABLET;ORAL

How can I launch a generic of NEXAVAR before it's drug patent expiration?
More Information on Dosage

NEXAVAR family patents

Family Patents

11. Safyral patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7163931 BAYER HLTHCARE Compositions of estrogen-cyclodextrin complexes
Mar, 2022

(1 year, 11 months ago)

US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(5 years from now)

US11617751 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Jul, 2030

(6 years from now)

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 16 December, 2010

Treatment: Prevention of pregnancy; Raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnan...

Dosage: TABLET;ORAL

How can I launch a generic of SAFYRAL before it's drug patent expiration?
More Information on Dosage

SAFYRAL family patents

Family Patents

12. Skyla patents expiration

SKYLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7252839 BAYER HLTHCARE Delivery system and a manufacturing process of a delivery system
Nov, 2023

(3 months ago)

US11628088 BAYER HLTHCARE Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection
Feb, 2027

(2 years from now)

US9615965 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US10561524 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US9668912 BAYER HLTHCARE Inserter
Apr, 2031

(7 years from now)

US10987244 BAYER HLTHCARE Inserter
Apr, 2031

(7 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 09 January, 2013

Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to rele...

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

SKYLA family patents

Family Patents

13. Staxyn patents expiration

STAXYN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8613950 BAYER HLTHCARE Pharmaceutical forms with improved pharmacokinetic properties
Dec, 2028

(4 years from now)

Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2010

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of STAXYN before it's drug patent expiration?
More Information on Dosage

STAXYN family patents

Family Patents

14. Stivarga patents expiration

STIVARGA's oppositions filed in EPO
STIVARGA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7351834 BAYER HLTHCARE ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jun, 2022

(1 year, 7 months ago)

US8637553 BAYER HLTHCARE Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Feb, 2031

(6 years from now)

US9957232 BAYER HLTHCARE 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Jul, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680124 BAYER HLTHCARE Treatment of cancers with acquired resistance to kit inhibitors
Jun, 2030

(6 years from now)

US9458107 BAYER HLTHCARE Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate
Apr, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 27, 2024

Drugs and Companies using REGORAFENIB ingredient

Market Authorisation Date: 27 September, 2012

Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kina...

Dosage: TABLET;ORAL

How can I launch a generic of STIVARGA before it's drug patent expiration?
More Information on Dosage

STIVARGA family patents

Family Patents

15. Vitrakvi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9127013 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(5 years from now)

US8513263 BAYER HLTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(5 years from now)

US10172861 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(11 years from now)

US10799505 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10005783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(5 years from now)

US10774085 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(5 years from now)

US10047097 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(5 years from now)

US9447104 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(5 years from now)

US9676783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Oct, 2029

(5 years from now)

US8865698 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Oct, 2029

(5 years from now)

US9782414 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(11 years from now)

US10285993 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(11 years from now)

US10813936 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 26, 2025

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

Market Authorisation Date: 26 November, 2018

Treatment: Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating...

Dosage: CAPSULE;ORAL

More Information on Dosage

VITRAKVI family patents

Family Patents

16. Xofigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635234 BAYER HLTHCARE Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
Nov, 2022

(1 year, 3 months ago)

Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient

Market Authorisation Date: 15 May, 2013

Treatment: Therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

XOFIGO family patents

Family Patents